Now, it’s worth noting Stock Advisor’s total average return is 1,041% — a market-crushing outperformance compared to 183 % ...

In the closing of the recent trading day, Gilead Sciences (GILD) stood at $113.03, denoting a -2.73% move from the preceding trading day.

Gilead Sciences (GILD) faces stock pressure as changes to the U.S. Preventive Services Task Force could impact PrEP drug ...

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Gilead ...

BMO Capital opined on Monday that recent reports indicating Robert F. Kennedy Jr.'s plan to remove all members of the U.S.

In celebration of the World Hepatitis Day (28 July), HCSA Community Services and Tan Tock Seng Hospital (TTSH), an anchor ...

Shares of Gilead Sciences (NASDAQ:GILD) dropped 2.8% Monday morning after reports emerged that U.S. Health and Human Services ...

Eli Lilly's appeal of a decision by the EMA's human medicines committee not to approve its Alzheimer's disease therapy ...

Lenacapavir can prevent 100 percent of HIV infections after just two injections per year, but getting it to SA could be a ...

Nontargeted hepatitis C screening leads to higher testing and diagnosis rates in the emergency department than targeted, risk ...

Visa will report its fiscal third quarter financial results on Tuesday, July 29. Analysts expect the company to report quarterly earnings at $2.85 per share. That’s up from $2.42 per share in the year ...

Greater awareness of viral infection’s impact and effective treatment options is crucial to stop it from progressing to more ...